Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1)
- 27 July 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (10) , 2777-2783
Abstract
Context Autosomal recessive hypophosphatemic rickets (ARHR) are rare, heritable renal phosphate-wasting disorders that arise from overexpression of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23) leading to impaired bone mineralization (rickets and osteomalacia). Inactivating mutations of Dentin matrix protein 1 (DMP1) give rise to ARHR type 1 (ARHR1). Short stature, prominent bowing of the legs, fractures/pseudofractures, and severe enthesopathy are prominent in this patient population. Traditionally, treatment consists of oral phosphate replacement and the addition of calcitriol but this approach is limited by modest efficacy and potential renal and gastrointestinal side effects. Objective The advent of burosumab (Crysvita), a fully humanized monoclonal antibody to FGF23 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, offers a unique opportunity to evaluate its safety and efficacy in patients with ARHR1. Results Monthly administration of burosumab to 2 brothers afflicted with the disorder resulted in normalization of serum phosphate, healing of pseudofracture, diminished fatigue, less bone pain, and reduced incapacity arising from the extensive enthesopathy and soft tissue fibrosis/calcification that characterizes this disorder. No adverse effects were reported following burosumab administration. Conclusion The present report highlights the beneficial biochemical and clinical outcomes associated with the use of burosumab in patients with ARHR1.Keywords
Funding Information
- Canadian Institutes of Health Research (156304))
This publication has 42 references indexed in Scilit:
- Hereditary disorders of renal phosphate wastingNature Reviews Nephrology, 2010
- FGF23 and the parathyroid glandsPediatric Nephrology, 2010
- Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutationJournal of Bone and Mineral Research, 2010
- Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 ConcentrationsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp MiceCalcified Tissue International, 2009
- Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic ricketsBone, 2009
- Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic RicketsClinical Journal of the American Society of Nephrology, 2008
- Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolismNature Genetics, 2006
- Ossification of the Posterior Longitudinal Ligament: An Update on Its Biology, Epidemiology, and Natural HistoryNeurosurgery, 2006
- Six Genes Expressed in Bones and Teeth Encode the Current Members of the SIBLING Family of ProteinsConnective Tissue Research, 2003